Does Rallies show 13F holders for IONS?

Yes. Rallies tracks hedge fund and 13F ownership data for IONS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IONS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IONS. It does not provide personalized investment advice.

IONS (Ionis Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Ionis Pharmaceuticals, Inc. Common Stock (IONS) is a publicly traded Healthcare sector company. As of May 21, 2026, IONS trades at $75.44 with a market cap of $11.98B and a P/E ratio of 74.97. IONS moved +1.63% today. Year to date, IONS is -4.42%; over the trailing twelve months it is +117.75%. Its 52-week range spans $23.95 to $86.74. Analyst consensus is strong buy with an average price target of $105.94. Rallies surfaces IONS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IONS stock?

Hedge funds tracked by Rallies that own IONS include Orbimed Advisors, Centerbook Partners, Eisler Capital, Bridgewater Associates, and Panagora Asset. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ionis Pharmaceuticals, Inc. Common Stock.

IONS Key Metrics

Key financial metrics for IONS
Metric	Value
Price	$75.44
Market Cap	$11.98B
P/E Ratio	74.97
EPS	$1.00
Dividend Yield	0.00%
52-Week High	$86.74
52-Week Low	$23.95
Volume	473
Avg Volume	0
Revenue (TTM)	$1.06B
Net Income	$154.57M
Gross Margin	98.35%

Top Hedge Funds Holding IONS

Orbimed Advisors holds 2.54M shares of IONS, changed -9.84% as of Mar 31, 2025.
Centerbook Partners holds 150.91K shares of IONS, changed -1.97% as of Mar 31, 2026.
Eisler Capital holds 117.56K shares of IONS, changed +622.59% as of Sep 30, 2024.
Bridgewater Associates holds 67.71K shares of IONS, changed +55.37% as of Dec 31, 2025.
Panagora Asset holds 57.45K shares of IONS, changed +0.00% as of Mar 31, 2026.

Latest IONS News

Tweedy Browne Cuts Ionis Stake Over 40% to 2.1M Shares — May 7, 2026
Ionis jumps as Q1 revenue nearly doubles and 2026 guidance is raised — Apr 29, 2026
Ionis Q1 Revenue Soars 87% to $246M While Loss Narrows to $75M — Apr 29, 2026
Ionis slips as investors digest large CFO stock sale disclosed in March Form 4 — Apr 16, 2026
Ionis jumps as TRYNGOLZA $40,000 repricing boosts expansion optimism into larger sHTG market — Apr 14, 2026

Recent IONS Insider Trades

Monia Brett P sold 3.22K (~$253.35K) on May 14, 2026.
Monia Brett P sold 1.32K (~$102.67K) on May 13, 2026.
LOSCALZO JOSEPH sold 59.51K (~$4.46M) on May 4, 2026.

IONS Analyst Consensus

17 analysts cover IONS: 0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $105.94.

Common questions about IONS

Who owns IONS stock?: Hedge funds tracked by Rallies that own IONS include Orbimed Advisors, Centerbook Partners, Eisler Capital, Bridgewater Associates, and Panagora Asset. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ionis Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for IONS?: Yes. Rallies tracks hedge fund and 13F ownership data for IONS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IONS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IONS. It does not provide personalized investment advice.